Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to -$1.5 million.

  • Akebia Therapeutics' Gains from Investment Securities fell 27102.8% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year increase of 18352.01%. This contributed to the annual value of -$622000.0 for FY2024, which is 14570.17% down from last year.
  • Akebia Therapeutics' Gains from Investment Securities amounted to -$1.5 million in Q3 2025, which was down 27102.8% from $7.0 million recorded in Q2 2025.
  • Over the past 5 years, Akebia Therapeutics' Gains from Investment Securities peaked at $51.3 million during Q4 2022, and registered a low of -$11.0 million during Q3 2022.
  • In the last 5 years, Akebia Therapeutics' Gains from Investment Securities had a median value of -$946000.0 in 2021 and averaged $1.5 million.
  • In the last 5 years, Akebia Therapeutics' Gains from Investment Securities tumbled by 2524545.45% in 2021 and then skyrocketed by 551997.89% in 2022.
  • Akebia Therapeutics' Gains from Investment Securities (Quarter) stood at -$946000.0 in 2021, then soared by 5519.98% to $51.3 million in 2022, then crashed by 113.29% to -$6.8 million in 2023, then soared by 110.61% to $723000.0 in 2024, then tumbled by 302.49% to -$1.5 million in 2025.
  • Its Gains from Investment Securities stands at -$1.5 million for Q3 2025, versus $7.0 million for Q2 2025 and $172000.0 for Q1 2025.